Implantable Medical Devices Having Multiblock Copolymers

• US 20100152831A1
• Filed: 12/12/2008
• Published: 06/17/2010
• Est. Priority Date: 12/12/2008
• Status: Abandoned Application

• Current Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Original Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Inventors: Guo, Ya, Udipi, Kishore
• Application Number:
  US12/333,642
• Publication Number:
  US 20100152831A1
• Time in Patent Office: Days
• US Class Current: 623/1.130
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

Provided herein are implantable medical devices comprising a biodegradable multiblock copolymer comprising at least three blocks; wherein the at least three blocks includes at least one inner block and two end blocks; further wherein each of the at least one inner block comprises monomers selected from the group consisting of e-caprolactone, r-butylactone, trimethylene carbonate, caprolactone derivatives, P-Dioxanone, and combinations thereof; and further wherein each of the end blocks comprises monomers selected from the group consisting of l-lactide, D-lactide, glycolide, L,D-lactide, and combinations thereof.

Claims

1. An implantable medical device comprising:

a biodegradable multiblock copolymer comprising at least three blocks;

wherein said at least three blocks includes at least one inner block and two end blocks;

further wherein each of said at least one inner block comprises monomers selected from the group consisting of e-caprolactone, r-butylactone, trimethylene carbonate, caprolactone derivatives, P-Dioxanone, and combinations thereof; and

further wherein each of said end blocks comprises monomers selected from the group consisting of l-lactide, D-lactide, glycolide, and L,D-lactide, and combinations thereof.

2. The implantable medical device of claim 1, wherein one of said at least one inner block is a center block.

3. The implantable medical device of claim 1, wherein each block is a homopolymer.

4. The implantable medical device of claim 1, wherein each block is a copolymer.

5. The implantable medical device of claim 2, wherein said center block is a soft block.

6. The implantable medical device of claim 1, wherein each of said end blocks is a hard block.

7. The implantable medical device of claim 2, wherein said at least three blocks alternate between a hard block and a soft block;

and further wherein said center block is a soft block; and

further wherein each of said end blocks is a hard block.

8. The implantable medical device of claim 1, wherein said multiblock copolymer is a triblock copolymer.

9. The implantable medical device of claim 8, wherein the center block is poly(trimethylenecarbonate) and the end blocks are poly(L-lactide-co-glycolide).

10. The implantable medical device of claim 1, wherein said biodegradable multiblock copolymer is cross-linked.

11. The implantable medical device of claim 1, wherein said end blocks serve as one or more cross-linking points.

12. The implantable medical device of claim 1, wherein said multiblock copolymer is an elastomer.

13. The implantable medical device of claim 1, further comprising at least one bioactive agent.

14. The implantable medical device of claim 13, wherein said at least one bioactive agent is selected from the group consisting of an antisense agent, an antineoplastic agent, an antiproliferative agent, an antithrombogenic agent, an anticoagulant, an antiplatelet agent, an antibiotic, an anti-inflammatory agent, a steroid, a gene therapy agent, a therapeutic substance, an organic drug, a pharmaceutical compound, a recombinant DNA product, a recombinant RNA product, a collagen, a collagenic derivative, a protein, a protein analog, a saccharide, a saccharide derivative, and combinations thereof.

15. The implantable medical device of claim 13, wherein said bioactive agent is zotarolimus.

16. The implantable medical device of claim 1, wherein said implantable medical device is selected from the group consisting of a vascular stent, stent graft, urethral stent, biliary stent, suture, ocular device, heart valve, shunt, pacemaker, bone screw, bone anchor, protective plate, prosthetic device, and combinations thereof.

17. The implantable medical device of claim 1, wherein said implantable medical device is a vascular stent.

18. The implant medical device of claim 1, wherein said implantable medical device is self-expanding.

19. A self-expanding vascular stent consisting essentially of:

a biodegradable triblock copolymer consisting essentially of

a poly(trimethylene carbonate) center block and two poly(L-lactide-co-glycolide) end blocks.

20. The self-expanding vascular stent of claim 19, further consisting essentially of a bioactive agent.